公开(公告)号：WO1998004157A1

公开(公告)日：1998-02-05

申请号：PCT/US1997012960

申请日：1997-07-23

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  SCHALLER, Joseph ,  ANDERSON, Steven, N. ,  MAZER, Terry, B. ,  HILTY, Milo, Duane ,  GUZMAN-HARTY, Melinda ,  LEE, Theresa, Siu-Ling, Wai ,  BOWMAN, Tammy, Marie ,  LAMM, Jill, M. ,  LIU, Jin-Zhou

IPC: A23L01/30

CPC classification number: A61K31/23 ,  A23L33/12

Abstract: A nutritional formulation containing an amount of diacetyltartaric acid esters of mono- and diglycerides effective to inhibit the infectious activity of pathogenic microorganisms is provided. A method of inhibiting the infectious activity of pathogenic microorganisms including the step of feeding the nutritional composition to a subject is also provided.

Abstract translation: 提供了含有一定量的有效抑制病原微生物的感染活性的单甘油酯和甘油二酯的二乙酰酒石酸酯的营养制剂。 还提供了抑制致病微生物感染活性的方法，包括将营养组合物喂给受试者的步骤。

公开(公告)号：WO1997017085A2

公开(公告)日：1997-05-15

申请号：PCT/US1996017860

申请日：1996-11-06

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  MUKERJI, Pradip ,  THURMOND, Jennifer, M. ,  HANSSON, Lennart ,  BAXTER, Jeffrey, H. ,  HARDS, Robert, G. ,  LEONARD, Amanda, Eun-Yeong ,  ANDERSON, Steven, N. ,  HARVEY, Linda, A.

IPC: A61K38/17

CPC classification number: C07K14/4732 ,  A23L33/19 ,  A61K38/00

Abstract: A method is provided for inhibiting the attachment of H. influenzae to human cells, such as pharyngeal cells, by contacting the bacilli with phosphorylated recombinant human beta -casein that have at least 3 phosphate groups. A product containing phosphorylated recombinant human beta -casein may be a liquid enteral nutritional product such as infant formula. The enteral nutritional product may be used for the prevention and treatment of otitis media in infants. The phosphorylated recombinant human beta -casein may also be administered as a throat spray or used in nose drops or a spray.

Abstract translation: 提供了通过使杆菌与具有至少3个磷酸基团的磷酸化重组人β-酪蛋白接触来抑制流感嗜血杆菌与人细胞如咽细胞的连接的方法。 含有磷酸化重组人β-酪蛋白的产品可以是液体肠内营养产品，如婴儿配方奶粉。 肠内营养产品可用于预防和治疗婴幼儿中耳炎。 磷酸化重组人β-酪蛋白也可以作为咽喉喷雾剂施用或用于鼻滴或喷雾剂中。

公开(公告)号：WO2004060859A2

公开(公告)日：2004-07-22

申请号：PCT/US2003/038906

申请日：2003-12-08

Applicant: ABBOTT LABORATORIES

Inventor： ANDERSON, Steven, N. ,  BHATIA, Pramila ,  KOLASA, Teodozyj ,  NAKANE, Masaki ,  PATEL, Meena, V. ,  ROHDE, Jeffrey, J. ,  XIA, Zhiren ,  ZHANG, Henry, Q.

IPC: C07C323/00

CPC classification number: C07D213/70 ,  C07C323/62 ,  C07D211/16 ,  C07D211/34 ,  C07D211/42 ,  C07D211/46 ,  C07D211/62

Abstract: Compounds of formula (I) are useful for increasing cGMP levels in a mammal.

Abstract translation: 式（I）化合物可用于增加哺乳动物的cGMP水平。

公开(公告)号：WO1998004513A1

公开(公告)日：1998-02-05

申请号：PCT/US1997012879

申请日：1997-07-23

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  MAZER, Terry, Bruce ,  ANDERSON, Steven, N. ,  GUZMAN-HARTY, Melinda ,  HILTY, Milo, Duane ,  LEE, Theresa, Siu-Ling, Wai ,  SHALLER, Joseph ,  LIU, Jin-Zhou

IPC: C07C69/70

CPC classification number: C07C69/70

Abstract: The present invention provides water-miscible lipid derivatives effective to inhibit the infectious activity of pathogenic microorganisms. Preferred water-miscible lipid derivatives are diacetyltartaric acid esters of monoglycerides wherein 90 percent or more of the fatty acid content is accounted for by a single fatty acid. The fatty acid component preferably contains from 8 to 24 and, more preferably, from about 10 to about 20 carbon atoms. The fatty acid can be saturated, unsaturated or hydroxylated.

Abstract translation: 本发明提供了有效抑制致病微生物感染活性的水混溶性脂质衍生物。 优选的水混溶性脂质衍生物是甘油单酯的二乙酰酒石酸酯，其中90％或更多的脂肪酸含量由单一脂肪酸占据。 脂肪酸组分优选含有8至24个，更优选约10至约20个碳原子。 脂肪酸可以是饱和的，不饱和的或羟基化的。

公开(公告)号：EP0918742B1

公开(公告)日：2002-09-18

申请号：EP97936999.8

申请日：1997-07-23

Applicant: Abbott Laboratories

Inventor： MAZER, Terry, Bruce ,  ANDERSON, Steven, N. ,  GUZMAN-HARTY, Melinda ,  HILTY, Milo, Duane ,  LEE, Theresa, Siu-Ling, Wai ,  SHALLER, Joseph ,  LIU, Jin-Zhou

IPC: C07C69/70

CPC classification number: C07C69/70

Abstract: The present invention provides water-miscible lipid derivatives effective to inhibit the infectious activity of pathogenic microorganisms. Preferred water-miscible lipid derivatives are diacetyltartaric acid esters of monoglycerides wherein 90 percent or more of the fatty acid content is accounted for by a single fatty acid. The fatty acid component preferably contains from 8 to 24 and, more preferably, from about 10 to about 20 carbon atoms. The fatty acid can be saturated, unsaturated or hydroxylated.

公开(公告)号：EP0920262A1

公开(公告)日：1999-06-09

申请号：EP97934281.0

申请日：1997-07-23

Applicant: Abbott Laboratories

Inventor： SCHALLER, Joseph ,  ANDERSON, Steven, N. ,  MAZER, Terry, B. ,  HILTY, Milo, Duane ,  GUZMAN-HARTY, Melinda ,  LEE, Theresa, Siu-Ling, Wai ,  BOWMAN, Tammy, Marie ,  LAMM, Jill, M. ,  LIU, Jin-Zhou

IPC: A23L1 ,  A61K31 ,  A61P31

CPC classification number: A61K31/23 ,  A23L33/12

Abstract: A nutritional formulation containing an amount of diacetyltartaric acid esters of mono- and diglycerides effective to inhibit the infectious activity of pathogenic microorganisms is provided. A method of inhibiting the infectious activity of pathogenic microorganisms including the step of feeding the nutritional composition to a subject is also provided.

公开(公告)号：EP0918742A1

公开(公告)日：1999-06-02

申请号：EP97936999.0

申请日：1997-07-23

Applicant: Abbott Laboratories

Inventor： MAZER, Terry, Bruce ,  ANDERSON, Steven, N. ,  GUZMAN-HARTY, Melinda ,  HILTY, Milo, Duane ,  LEE, Theresa, Siu-Ling, Wai ,  SHALLER, Joseph ,  LIU, Jin-Zhou

IPC: A61P31 ,  A61K31 ,  C07C69

CPC classification number: C07C69/70

Abstract: The present invention provides water-miscible lipid derivatives effective to inhibit the infectious activity of pathogenic microorganisms. Preferred water-miscible lipid derivatives are diacetyltartaric acid esters of monoglycerides wherein 90 percent or more of the fatty acid content is accounted for by a single fatty acid. The fatty acid component preferably contains from 8 to 24 and, more preferably, from about 10 to about 20 carbon atoms. The fatty acid can be saturated, unsaturated or hydroxylated.

公开(公告)号：EP0862450A2

公开(公告)日：1998-09-09

申请号：EP96938817.0

申请日：1996-11-06

Applicant: Abbott Laboratories

Inventor： MUKERJI, Pradip ,  THURMOND, Jennifer, M. ,  HANSSON, Lennart ,  BAXTER, Jeffrey, H. ,  HARDS, Robert, G. ,  LEONARD, Amanda, Eun-Yeong ,  ANDERSON, Steven, N. ,  HARVEY, Linda, A.

IPC: C12N15 ,  A23L1 ,  A61K31 ,  A61K38 ,  A61P27 ,  A61P31 ,  C07K14

CPC classification number: C07K14/4732 ,  A23L33/19 ,  A61K38/00

Abstract: A method is provided for inhibiting the attachment of H. influenzae to human cells, such as pharyngeal cells, by contacting the bacilli with phosphorylated recombinant human β-casein that have at least 3 phosphate groups. A product containing phosphorylated recombinant human β-casein may be a liquid enteral nutritional product such as infant formula. The enteral nutritional product may be used for the prevention and treatment of otitis media in infants. The phosphorylated recombinant human β-casein may also be administered as a throat spray or used in nose drops or a spray.